07 Mar 2025: PinoBio announces results of dual-payload ADC platform research
PinoBio presented research at World ADC London 2025, demonstrating the superior efficacy of its dual-payload ADC platform compared to single-payload ADCs
The platform utilizes PBX-7016, a TOP1 inhibitor, and MMAE, a microtubule inhibitor, with a stable manufacturing method ensuring uniform ADCs
Dual-payload ADC showed superior efficacy compared to single-payload ADCs in both in vivo and in vitro studies
Safety was confirmed with no adverse reactions in primate toxicity evaluations, even at high doses, with favorable pharmacokinetic behavior
PinoBio aims to enhance ADC technology by maintaining safety while improving efficacy to overcome limitations of single-payload ADCs